Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 10.30%
As of Friday, August 21, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 10.30%, which has investors questioning if this is right time to sell.Omar Beirat
Stock Evaluator: SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. SLS
$15.46
2.06
15.37%
August 21, 2026 4:00:00 PM
EST
Volume: 15,203,642
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Commentary & Analysis
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 6.87%
As of Friday, August 21, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 6.87%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 6.87%
As of Wednesday, August 19, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 6.87%, which has investors questioning if this is right time to sell.Jenna Brashear
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 7.69%
As of Wednesday, August 12, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 7.69%, which has investors questioning if this is right time to sell.Jenna Brashear
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 6.59%
As of Monday, August 03, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 6.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,706.1 | $286.3 | 58% |
|
| Shares Out (Mil) | 189.2 | 54.2 | 75% |
|
| Institutional Ownership | 98.9% | 92.8% | 83% |
|
| Float (Mil) | 201.1 | 39.7 | 74% |
|
| Beta | 2.49 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 6,023 | 534 | 94% |
|
| Price Change (52-week) |
688.2% | 58.7% | 100% |
|
| Growth | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (9.9%) | (10.1%) | 29% |
|
| EPS (5yr) | 34.9% | 16.0% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (31.5%) | (15.6%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.050) | ($0.200) | ($0.100) | |
| Month Ago EPS | ($0.055) | ($0.210) | ($0.125) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.055) | ($0.210) | ($0.150) | |
| Year/Year Chg | (2.0%) | (18.7%) | (116.3%) | |
| Financials | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($33) | ($43) | 20% |
|
| EPS (TTM) | ($0.212) | ($1.400) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $2,239 | $160 | 50% |
|
| Valuation | SLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 19.71 | 2.77 | 95% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (36.5%) | (47.3%) | 15% |
|
| ROE | (39.6%) | (55.0%) | 17% |
|
| Liabilities to Assets | 5.3% | 29.6% | 2% |
|
| F-Score | 4 | 2 | 34% |
|
SELLAS Life Sciences Group, Inc. did not pass any screens on 8/20/2026.
